Efficacy and tolerability of osimertinib with dabrafenib and trametinib in V600E acquired -mutant non-small cell lung cancer: a case series.

Background: Acquired mutations within bypass pathways including V600E have been observed in post-osimertinib progression in -mutant non-small cell lung cancer (NSCLC). The combination of dabrafenib and trametinib is currently Food and Drug Administration-approved in V600E-mutant NSCLC. However, the application of osimertinib and dabrafenib and trametinib in the setting of acquired V600E mutation resistance from osimertinib therapy has not been clearly defined.